The strong growth in topline helped the healthcare company generate adjusted EPS of $1.84 per share in Q3, which was 7 cents ahead of the street consensus.
“All of our core businesses performed in line with or above expectations, reflecting strong operational execution. As a result, we delivered strong growth and generated robust operating cash flow, which enabled us to continue to deliver while returning capital to our shareholders,” CEO Larry Merlo stated.
READ: Alteryx CFO Kevin Rubin on Q4 outlook, stock sell-off and the possibility of getting acquired
Outlook raised
Thanks to the strong results, the company raised and narrowed its Adjusted EPS guidance range to $6.97 – $7.05 from the prior projection of $6.89 – $7.00.
Meanwhile, outlook on GAAP operating income was slashed to $11.77 billion – $11.95 billion from the earlier range of $11.82 billion – $12.02 billion.
CVS shares gained 1.5% during pre-market hours.